Kinetic Studies on the Inhibition Potential of Bitter Leaf (Vernonia Amygdalin) in the Management of Diabetes

The aim of this study was to investigate the inhibition potential of extracts from Vernonia amygdalina on α-amylase and α-glucosidase activity, and its useful mechanisms in the treatment of diabetes specifically Type 2. The searchlight is beamed on the potential of the plant extract to inhibit the activity of α-amylase and thereby determining its mechanism or mode on inhibition as well as its IC₅₀ value. The inhibition of alpha-amylase and alpha-glucosidase enzymes is a key strategy in managing diabetes. Vernonia amygdalina is a natural plant extract that has been used traditionally to manage diabetes. In this study, the inhibition potential of Vernonia amygdalina on alpha-amylase and alpha-glucosidase was investigated. Kinetic studies were conducted to determine the inhibitory effects of the plant extract on these enzymes. The results showed that vernonia amygdalina exhibited significant inhibition of both alpha-amylase and alpha-glucosidase enzymes. The study also evaluated the kinetic parameters of the inhibition process, including the type of inhibition and the inhibition constant. The findings of this study suggest that Vernonia amygdalina has the potential to be used as a natural inhibitor of alpha-amylase and alpha-glucosidase enzymes, which could lead to the development of new natural remedies for managing diabetes. These results are of interest to researchers studying natural product chemistry and drug development and inhibition of enzyme in bioreactors. Vernonia amygdalina inhibits alpha-amylase and alpha glucosidase activities but with greater inhibitory effects experienced in alpha glucosidase shows that plants tend to have higher inhibitory effect on alpha-glucosidase. With the obtain IC₅₀ values it helps to provide insight into the mechanism of actions of an inhibitor by helping to determine the nature and strength of the interaction between the inhibitor and the enzyme or the biological process being inhibited. Acarbose which serves as inhibitors of these enzymes with greater effect on alpha-amylase but resulting to gastrointestinal adverse effects due to the accumulation of undigested carbohydrates becoming readily available for bacterial fermentation. With these outcomes the possibility exists that controlling glycemic complication is achievable by combining the inhibitory effect of Vernonia amygdalina and acarbose while reducing acarbose dose to alleviate anti-diabetic related adverse effects. Further investigation and studies are warranted in humans to help in glycemic control while in bioreactors this may include the usage of alpha-glucosidase and alpha-amylase as enzyme which similarly employs Vernonia amygdalina. It is noteworthy that the activity of these enzymes can be inhibited in bioreactors.